Contact   |   Login
EquinYar Banner Image


EquinYar™ Classic is based on our proprietary and patent-protected strain of Yarrowia lipolytica yeast ( 5902596870171, 5902596870539 )

EquinYar Joints is a unique composition supporting the osteoarticular system and preventing degenerative changes. Thanks to a high bioavailability of nutrients, it quickly compensates mineral deficiencies and enriches the body with amino acids, that play an important role in the reconstruction and regeneration of joint cartilage. The active ingredients participate in type I and II collagen synthesis. Additionally, chondroitin stimulates the production of proteoglycans of joint cartilage, thus supporting its regeneration whilst glucosamine increase the production of synovia.

Contact our Customer Support Department to find out how we can address your needs in your market.

Catalog Download:

To download the latest catalog for EquinYar, click here.

Quick Contact

Catalog Download:
To download the latest catalog for EquinYar Feed Supplements, click here.

Deferoxamine Mesylate Market to Witness Robust Expansion by 2029 with Teva api, Chengdu Easton Biopharmaceuticals, Pharmapex Group
The Deferoxamine Mesylate Report is a unique record that gives a total judgment of the market in terms of future patterns, development factors, creation volume, CAGR estimation, net revenue, cost, and industry-approved market data.

Pharmapex's novel mastitis treatment offers hope to world farmers
Efficient feed-based mastitis treatment boosts livestock health with a unique microencapsulated technology.

FDA approves Farxiga to treat type 2 diabetes
The U.S. FDA today approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
© , Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved.